📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?: Can we avoid a catastrophic second valley of death? (2023)

First Author: De Luca M

Attributed to: Cell mediated gene therapy for Duchenne muscular dystrophy: trans-correction of resident nuclei to amplify dystrophin expression funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.15252/embr.202256661

PubMed Identifier: 36592141

Publication URI: http://europepmc.org/abstract/MED/36592141

Type: Journal Article/Review

Volume: 24

Parent Publication: EMBO reports

Issue: 2

ISSN: 1469-221X